Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.38B+690%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.35B+176%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.14B+874%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$2.01B+78.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$6.74B+280%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Calculated from MoonLake Immunotherapeutics’s reported figures.

$1.3Bmarket cap+$100.8Mtotal debt−$298.5Mcash and equivalents=$1.14B

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's enterprise value?
MoonLake Immunotherapeutics (MLTX) reported enterprise value of $1.14B in Q1 2026.
How has MoonLake Immunotherapeutics's enterprise value changed year-over-year?
MoonLake Immunotherapeutics's enterprise value decreased by 50.0% year-over-year, from $2.28B to $1.14B.
What is the long-term trend for MoonLake Immunotherapeutics's enterprise value?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's enterprise value has grown at a 16.0% compound annual growth rate (CAGR), from $372.59M to $674.96M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.